This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Revisiting Some Speculative Plays

Editor's Note: This was originally published as an alert at 11:20 a.m. EST on Dec. 23 to subscribers of's Stocks Under $10. The stock prices and returns have been updated to reflect today's levels.

Earlier this month we put together a basket of five low-priced stocks that we believed would outperform the market in December due to increased investor demand for speculative stocks. The moves we were seeing in stocks like Sirius (SIRI - Get Report) and Genta (GNTA) seeded this concept.

Here they are again, along with a performance table to track our performance:

Stemcells (STEM - Get Report) is up 22% at $3.62.
Aphton (APHT) is off 2.5% at $3.14.
E-Loan (EELN) is up 15% at $3.31.
Tut Systems (TUTS) is up 2.4% at $3.84.
OpenTV (OPTV) is essentially flat at $3.82.

Last night we had two double-digit gainers; Aphton and E-Loan, and today, we can add Stemcells to the list. News that stem cells could be used to treat often-fatal cystic fibrosis has the stock trading 15% higher to $3.58 a share. (Geron, our stem-cell play in the model portfolio, already has climbed 15% this week.)

We would be locking in gains in some of the names today if we owned them for our model portfolio, and now we want to elaborate on why this portfolio worked.

On the whole, the portfolio is 7% higher than the Dec. 8 entry prices, while the S&P 500 is up 2.97% during the same period. (Readers who took some gains off the table in Aphton on Dec. 10 and E-Loan on Dec. 10 and Dec. 15 have a 10.92% gain.)

We would close out of Aphton here for a 10.91% gain. No phase III data have been reported yet for its gastrointestinal cancer vaccine, and we view the risk/reward here as more negative than it was earlier this month.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SIRI $3.96 -0.13%
STEM $0.30 -2.00%
AAPL $94.79 1.20%
FB $118.08 -0.41%
GOOG $693.79 -0.63%


Chart of I:DJI
DOW 17,717.79 -173.37 -0.97%
S&P 500 2,059.08 -22.35 -1.07%
NASDAQ 4,759.32 -58.2740 -1.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs